Journal List > J Korean Ophthalmol Soc > v.59(10) > 1103093

J Korean Ophthalmol Soc. 2018 Oct;59(10):915-921. Korean.
Published online October 17, 2018.  https://doi.org/10.3341/jkos.2018.59.10.915
©2018 The Korean Ophthalmological Society
Selective Retina Therapy in Patients with Central Serous Chorioretinopathy
Jae Min Kim, MD and Joo Yeon Kim, MD
Myung-Gok Eye Resarch Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea.

Address reprint requests to Joo Yeon Kim, MD. Department of Ophthalmology, Kim's Eye Hospital, #136 Yeongsin-ro, Yeongdeungpo-gu, Seoul 07301, Korea. Tel: 82-2-2639-7777, Fax: 82-2-2639-7766, Email: redmanson@kimeye.com
Received December 14, 2017; Revised May 21, 2018; Accepted September 27, 2018.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Purpose

We evaluated the visual outcomes and changes in central macular thickness in patients with central serous chorioretinopathy who underwent selective retina therapy.

Methods

Patients diagnosed with central serous chorioretinopathy were included in the study. Fundus fluorescein angiography was performed before laser treatment. We reviewed the charts of 16 patients (17 eyes) in terms of age, sex, best-corrected visual acuity, intraocular pressure, slit lamp examination, the time from diagnosis to laser treatment, the site of laser treatment and side-effects. Optical coherence tomography was performed before laser treatment and 1 month later; the central macular thicknesses were compared.

Results

The average best-corrected visual acuity at diagnosis and 1 month after laser treatment were 0.20 and 0.12 (logMAR) respectively. The improvement was thus 0.08 (logMAR). The average central macular thickness decreased by 174.78 µm from 326.53 ± 59 µm at baseline to 151.75 ± 15 μm 1 month after selective retina therapy.

Conclusions

Selective laser therapy afforded favorable visual and structural outcomes and was not associated with a risk of scotoma or other untreatable side-effects.

Keywords: Best correct visual acuity; Central macular thickness; Central serous chorioretinopathy; Selective retina therapy

Figures


Figure 1
Case 12. Selective laser therapy was applied to the leakage point which is indicated by dotted circle on fundus fluorescin angiography at baseline.
Click for larger image


Figure 2
Case 5. Large subretinal fluid was observed on baseline optical coherence tomography.
Click for larger image


Figure 3
Case 5. The subretinal fluid were completely resolved at 1 months after selective retina therapy.
Click for larger image

Tables


Table 1
Characteristics of 16 patients (17 eyes) with central serous chorioretinopathy
Click for larger image


Table 2
Change of best-corrected visual acuity (logMAR) in selective retina therapy-treated patients with central serous chorioretinopathy
Click for larger image


Table 3
Change of central retinal thickness (CRT) in selective retina therapy-treated patients with central serous chorioretinopathy
Click for larger image

Notes

Conflicts of Interest:The authors have no conflicts to disclose.

References
1. Fujita K, Shinoda K, Matsumoto CS, et al. Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy. Clin Ophthalmol 2012;6:1681–1687.
2. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126–145.
3. Oh J, Kwon OW, Kim MH, et al. Photodynamic therapy for chronic central serous chorioretinopathy: multicenter study of 65 cases. J Korean Ophthalmol Soc 2009;50:390–398.
4. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63 Suppl 1:1–139.
5. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984;91:1554–1572.
6. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288–298.
7. Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 1995;120:65–74.
8. Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretionpathy. Br J Ophthalmol 2005;89:562–564.
9. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986;224:321–324.
10. Spaide RF, Goldbaum M, Wong DW, et al. Serous detachment of the retina. Retina 2003;23:820–846.
11. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010;149:361–363.
12. Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 2013;41:187–200.
13. Wood EH, Karth PA, Sanislo SR, et al. Nondamaging retial laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina 2017;37:1021–1033.
14. Roider J, Brinkmann R, Wirbelauer C, et al. Retinal sparing by selective retinal pigment epithelial photocoagulation. Arch Ophthalmol 1999;117:1028–1034.
15. Brinkmann R, Roider J, Birngruber R. Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006;(302):51–69.
16. Roider J, Liew SH, Klatt C, et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2010;248:1263–1272.
17. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.
18. Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond) 2016;30:1371–1377.
19. Kang S, Park YG, Kim JR, et al. Selective retina therapy in patients with chronic central serous chorioretinopathy: a pilot study. Medicine (Baltimore) 2016;95:e2524
20. Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 2011;95:83–88.
21. Brinkmann R, Roider J, Birngruber R. Selective retina therapy( SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006;302:51–69.
22. Elsner H, Pörksen E, Klatt C, et al. Selective retina therapy in patients with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006;244:1638–1645.
23. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011;22:166–173.
24. Framme C, Walter A, Berger L, et al. Selective retina therapy in acute and chronic-recurrent central serous chorioretinopathy. Ophthalmologica 2015;234:177–188.